

public review and comment. Interested persons may, on or before November 22, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: October 10, 1995.

Alan M. Rulis,

*Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 95-26153 Filed 10-20-95; 8:45 am]

BILLING CODE 4160-01-F

## National Institutes of Health

### Prospective Grant of Exclusive License: Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Application Serial Number 08/231,565, entitled "Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods" and related foreign patent applications to Therion Biologics Corporation, of Cambridge, Massachusetts. The patent rights in this invention have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This license will be limited to the field of treatment and/

or prevention of cancer in humans using recombinant poxviruses comprising melanoma antigens. The melanoma antigens may be limited to MART-1 and gp100, encoded by Sequence ID Nos. 1 and 26 (described in patent application 08/231,565), respectively, and fragments thereof. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent application describes nucleic acid sequences that encode novel melanoma antigens MART-1 and gp100, recombinant protein MART-1 and gp100, peptides from MART-1 and gp100 which react with tumor infiltrating lymphocytes (TIL cells), and recombinant expression vectors comprising nucleic acids that encode MART-1 or gp100, and fragments thereof.

**ADDRESSES:** Requests for a copy of this patent application (which require a signed confidential disclosure agreement), inquiries, comments and other materials relating to the contemplated license should be directed to: Raphe Kantor, Ph.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone: 301/496-7735, ext 247; Facsimile: 301/402-0220. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before December 22, 1995 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 11, 1995.

Barbara M. McGarey,

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 95-26189 Filed 10-20-95; 8:45 am]

BILLING CODE 4140-01-P

## Public Health Service

### National Center for Health Statistics; the ICD-9-CM Coordination and Maintenance Committee; Notice

**AGENCY:** National Center for Health Statistics, DHHS.

**ACTION:** Notice of meeting.

**SUMMARY:** The ICD-9-CM Coordination and Maintenance Committee (C&M) will be holding its final meeting of the year on Thursday, November 30, 1995. The C&M meeting is a public forum for the presentation of proposed modifications to the International Classification of Diseases, ninth-revision, clinical modification.

**DATES:** The meeting will be held on November 30, 1995 from 9 a.m.-5 p.m.

**ADDRESS:** The Hubert H. Humphrey building, rm. 703A, 200 Independence Ave. Washington, D.C.

**NOTICE:** In the interest of security, the Humphrey building has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D., sign-in, and be escorted up to the meeting room. Please arrive prior to the 9 a.m. start time of the meeting to assure an escort will be available. Entrance to the meeting after 9 a.m. cannot be assured.

**FOR FURTHER INFORMATION CONTACT:** Amy Blum 301-436-4216.

### SUPPLEMENTARY INFORMATION:

Tentative Agenda

Child/Adult Abuse

Factitious Disorder by Proxy

Mental Health Disorders

Immunization V codes

External Cause of Injury

Development of ICD-10 Procedure Classification

Noncoronary stents

Endometrial ablation

Pancreatic islet cell transplant

Laparoscopic/thoroscopic procedures

Addenda

Sue Meads,

*R.R.A., Co-chair, ICD-9-CM Coordination and Maintenance Committee.*

[FR Doc. 95-26093 Filed 10-20-95; 8:45 am]

BILLING CODE 4160-18-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

### Office of the Secretary

[Docket No. FR-3926-D-01]

### Designating Attesting Officers

**AGENCY:** Office of the Secretary, HUD.

**ACTION:** Delegation of authority to cause department seal to be affixed and to authenticate copies of documents.

**SUMMARY:** This delegation of authority revises and updates the designation of attesting officers to authenticate documents.